Indaptus Therapeutics, Inc..
INDP.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Indaptus Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a novel class of immunotherapeutic agents that mobilize a patient’s immune system to eliminate cancer cells. Their primary focus is on developing therapies that target and eliminate immunosuppressive cell...Show More
Better Health for All
0
No evidence available to assess Indaptus Therapeutics, Inc. on Better Health for All.
Fair Money & Economic Opportunity
0
Indaptus Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments.
1
The company's core business does not involve lending, insuring, moving, or storing money, nor does it offer financial products or services to consumers.
2
Therefore, all KPIs related to fair money and economic opportunity, which are designed for financial institutions, are not applicable to Indaptus Therapeutics' operations.
3
Fair Pay & Worker Respect
0
No evidence available to assess Indaptus Therapeutics, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No specific, concrete data points were found in the provided articles for any of the KPIs related to Fair Trade & Ethical Sourcing. While the company has a Code of Business Conduct and Ethics that mentions fair dealing with suppliers and legal compliance, this does not provide quantitative evidence for fair-trade certification, audit frequency, forced/child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in supplier contracts, materials risk index, or supplier diversity spend.
1
Honest & Fair Business
0
No specific, concrete data points were found across the provided articles to assess Indaptus Therapeutics, Inc. against any of the 'Honest & Fair Business' KPIs.
1
Information regarding regulatory fines, transparency index scores, whistleblower policies, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict-free percentages, anti-corruption policies, or third-party verification was not available for the company.
2
Kind to Animals
-50
Indaptus Therapeutics conducts preclinical studies involving animals, including mice and human tumor xenografts, as part of its drug development process.
1
These animal studies are performed in accordance with Good Laboratory Practices (GLP) regulations, and the company relies on third parties to conduct them.
2
The company's R&D expenses for the year ended December 31, 2024, were approximately $7.25 million, and for 2023, they were $7.6 million.
3
There is no specific percentage of this budget allocated to animal-free technologies, but the company is dedicated to pioneering innovative treatments.
4
The articles do not provide specific data on the number of animals used annually, but they indicate the use of mouse models for various preclinical tests, including HCC and AAV-HBV models, without transparent reduction targets.
5
No War, No Weapons
0
The provided articles for Indaptus Therapeutics, Inc. (INDP.US) do not contain any specific, concrete data points or verifiable facts relevant to the 'No War, No Weapons' ethical value. The company's annual reports and other articles focus on its clinical-stage biotechnology operations, financial performance, and general corporate ethics policies. There is no information regarding revenue from arms or defense contracts, investment in dual-use technologies, sales to embargoed regimes, peacebuilding initiatives, conflict divestment policies, board oversight of defense activities, export end-user certifications, lobbying related to arms control, humanitarian procurement, human rights due diligence in conflict areas, Arms Trade Treaty compliance, AI military safeguards, UN Guiding Principles alignment, dual-use item screening, surveillance transparency, ethical red lines for weapons, exposure to controversial weapons, war-related supply chain risk audits, annual conflict partner reviews, defense divestment, conflict minerals, peace technology investment, or procurement from conflict zones.
1
Therefore, no KPIs can be scored based on the available evidence.
Planet-Friendly Business
0
No information is available regarding Indaptus Therapeutics, Inc.'s environmental performance or initiatives. The provided articles, including annual reports, SEC filings, and company website information, do not contain any data on carbon emissions, renewable energy use, water consumption, waste diversion, green building certifications, or any other planet-friendly business metrics.
1
Therefore, no assessment can be made against the specified KPIs.
Respect for Cultures & Communities
0
The provided articles, which include an annual financial report
1
and a code of business conduct
2
, do not contain specific, concrete data points or information relevant to Indaptus Therapeutics' performance regarding 'Respect for Cultures & Communities'. There is no evidence concerning formal partnerships with community groups, reinvestment in local development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, community grievance mechanisms, cultural preservation investments, or any other metrics outlined in the rubric for this ethical value.
3
Safe & Smart Tech
0
No evidence available to assess Indaptus Therapeutics, Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
-40
Indaptus Therapeutics reports waste diversion rates for specific streams: 18.3% for biological waste, 27.5% for chemical waste, and 24.6% for plastic materials.
1
The company has implemented comprehensive recycling protocols for its chemical and biological waste streams, indicating active hazardous waste management.
2